48,833
edits
Difference between revisions of "Salivary duct carcinoma"
Jump to navigation
Jump to search
Salivary duct carcinoma (view source)
Revision as of 00:58, 10 February 2016
, 00:58, 10 February 2016→IHC
(→IHC) |
|||
| Line 74: | Line 74: | ||
==IHC== | ==IHC== | ||
*LMWK, EMA, CK7, CK19 +ve. | *LMWK, EMA, CK7, CK19 +ve. | ||
*p63 -ve. | *[[p63]] -ve. | ||
*Androgen receptor +ve (~90% of cases).<ref name=pmid10757407>{{Cite journal | last1 = Fan | first1 = CY. | last2 = Wang | first2 = J. | last3 = Barnes | first3 = EL. | title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. | journal = Am J Surg Pathol | volume = 24 | issue = 4 | pages = 579-86 | month = Apr | year = 2000 | doi = | PMID = 10757407 }}</ref> | *[[Androgen receptor]] +ve (~90% of cases).<ref name=pmid10757407>{{Cite journal | last1 = Fan | first1 = CY. | last2 = Wang | first2 = J. | last3 = Barnes | first3 = EL. | title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. | journal = Am J Surg Pathol | volume = 24 | issue = 4 | pages = 579-86 | month = Apr | year = 2000 | doi = | PMID = 10757407 }}</ref> | ||
*BRST2 ([[GCDFP-15]]) +ve. | *BRST2 ([[GCDFP-15]]) +ve. | ||
*HER2 +ve ~21%; use of [[trastuzumab]] (Herceptin) not systematically studied. | *HER2 +ve ~21%; use of [[trastuzumab]] (Herceptin) not systematically studied. | ||